GenFleet Therapeutics (Shanghai) (HAM:Y3L) Beginning Cash Position: €42.02 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:Y3L GenFleet Therapeutics (Shanghai) Inc HAM:Y3L
19 GF Score
Price €2.92
! 3 Warning Signs
View Full Analysis

What is GenFleet Therapeutics (Shanghai) Beginning Cash Position?

GenFleet Therapeutics (Shanghai) HAM:Y3L -2.80% 19 Beginning Cash Position is €42.02 Mil as of Dec. 2025. GuruFocus rates HAM:Y3L with a GF Score™ of 19/100. The stock has 3 warning signs investors should review.

GenFleet Therapeutics (Shanghai)'s Beginning Cash Position for the quarter that ended in Dec. 2025 was €42.02 Mil.

GenFleet Therapeutics (Shanghai)'s quarterly Beginning Cash Position increased from Dec. 2024 (€36.60 Mil) to Jun. 2025 (€43.72 Mil) but then declined from Jun. 2025 (€43.72 Mil) to Dec. 2025 (€42.02 Mil).

GenFleet Therapeutics (Shanghai)'s annual Beginning Cash Position increased from Dec. 2023 (€37.93 Mil) to Dec. 2024 (€43.57 Mil) and increased from Dec. 2024 (€43.57 Mil) to Dec. 2025 (€43.91 Mil).

GenFleet Therapeutics (Shanghai) Beginning Cash Position Related Terms

GenFleet Therapeutics (Shanghai) Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for GenFleet Therapeutics (Shanghai)'s Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GenFleet Therapeutics (Shanghai) Beginning Cash Position Chart

GenFleet Therapeutics (Shanghai) Annual Data
Trend Dec23 Dec24 Dec25
Beginning Cash Position
37.93 43.57 43.91

GenFleet Therapeutics (Shanghai) Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position 0.00 42.54 36.60 43.72 42.02
HAM:Y3L
19GF Score
GenFleet Therapeutics (Shanghai) Inc HAM:Y3L
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GenFleet Therapeutics (Shanghai) Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €42.02 Mil mean?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a Beginning Cash Position of €42.02 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on GenFleet Therapeutics (Shanghai) and its competitors.
Is GenFleet Therapeutics (Shanghai)'s Beginning Cash Position too high?
GenFleet Therapeutics (Shanghai)'s current Beginning Cash Position is €42.02 Mil. Overall, GenFleet Therapeutics (Shanghai) has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does GenFleet Therapeutics (Shanghai)'s Beginning Cash Position compare to VRTX and REGN?
GenFleet Therapeutics (Shanghai)'s Beginning Cash Position of €42.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. GenFleet Therapeutics (Shanghai)'s current Beginning Cash Position is €42.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenFleet Therapeutics (Shanghai) stock overvalued right now?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a current Beginning Cash Position of €42.02 Mil. The current Beginning Cash Position is €42.02 Mil. GenFleet Therapeutics (Shanghai)'s overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For GenFleet Therapeutics (Shanghai) (HAM:Y3L), the current Beginning Cash Position is €42.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GenFleet Therapeutics (Shanghai) Business Description

Other Exchanges 02595:Hong Kong
Address 1206 Zhangjiang Road, Floors 2nd, 3rd, 4th, and 5th, Building 8, Shanghai Pilot Free Trade Zone, Shanghai, CHN, 201203
GenFleet Therapeutics (Shanghai) Inc Company is a clinical-stage biotechnology company. The Company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment.
19GF Score

Get the complete analysis for HAM:Y3L

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.92
Price